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for preventing Trichinella spiralis infection. We have previously
reported that a recombinant Ts87 protein was considered as a
potential candidate vaccine for Trichinella spiralis. In this study
mucosal immune responses induced by SL7207/pvax1-Ts87 were
assessed.
Methods: We constructed a recombinant plasmid pvax1-Ts87,
and evaluated safety, stability of SL7207/pvax1-Ts87, a DNA
vaccine delivered in attenuated Salmonella typhimurium, and
immune responses induced by immunizing BALB/c mice orally
with SL7207/pvax1-Ts87 of 108 CFU dosage. After the ﬁnal boost,
mice were challenged orally with 500 Trichinella spiralis infec-
tive muscle larvae for per mouse.
Results: Oral immunization of mice with SL7207/pvax1-Ts87
elicited signiﬁcant elevation of intestinal secretory IgA and
serum anti-Ts87 IgG. The immunized mice exhibited a high ratio
of IgG1 to IgG2a. Splenocytes were isolated after the immu-
nization to determine the antigen-speciﬁc T-cell response by the
ELISPOT assay. The result showed that CD4+ T cells produced
IFN-γ, IL-4, IL-5, IL-6 and IL-10. Immunoﬂuorescent microscopy
revealed that the recombinant Ts87 protein was expressed in the
dendritic cells of mesenteric lymph nodes. Furthermore BALB/c
mice vaccinated with SL7207/pvax1-Ts87 demonstrated 29.8%
reduction in adult worm burden and muscle larval reduction
(34.2%) following Trichinella spiralis larvae challenge.
Conclusion: Our results demonstrated a SL7207/pvax1-Ts87 DNA
vaccine delivered in attenuated Salmonella typhimurium can
elicit speciﬁc immune response as well as provide effective
protection against Trichinella spiralis infection in mice.
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PL-004 Protective effect of bone-marrow-derived
mesenchymal stem cells on ischemic reperfusion
injury of rat liver graft after reduced-size liver
transplantation
Hongli Song*, Xiaojing Song, Weiping Zheng, Zhongyang Shen.
Department of Organ Transplantation, Tianjin the First Central
Hospital
Objective: To observe the distribution and amount of bone-
marrow-derived mesenchymal stem cells (BMSCs) after reduced-
size liver transplantation in rats and study the effect of BMSCs in
promoting the recovery of ischemic reperfusion injury.
Methods: 1. BMSCs were isolated from femur in the rat by the
density gradient centrifugation and puriﬁed. 2. All reduced-size
liver transplantation models were divided into 2 groups (each
group having 18 recipients)as follow: Wistar donor liver to Wistar
recipient, 1ml (5×106/ml) BMSCs of the third generation and
labeled (treat group) and 1ml PBS (control group) were injected
into portal vein, respectively. At the 2nd, 3rd and 7th day after
transplantation, liver and serum samples were collected. By us-
ing biochemistry, Immunohistochemistry, Flow CytoMeter and the
biochemical indicator were detect and counted. The distribution
of BMSCs in the frozen section was observed by ﬂuorescence.
The mechanism of the reparation of ischemic reperfusion injury
was explored through observation of the trace of CFSE-labeling
donator’s BMSCs in recipient’s body.
Results: The injured hepatic tissues were repaired. The green
ﬂuorescent cells were found in the recovery of the host liver tis-
sue, central veins and sinus hepaticus. The number of tetraploid
cell in treat group was signiﬁcantly inhibited in control group
(p=0.024).
Conclusion: BMSCs can successfully reside in the liver of rats and
the homing status of BMSCs is closely associated with quantity
of stem cells and the damage status of liver. BMSCs can protect
hepatic ischemic reperfusion injury.
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PL-005 Proﬁle of HBsAg levels in patients with dual
hepatitis B virus and hepatitis C virus infection
treated with peginterferon alfa-2a and ribavirin
Chun-Jen Liu*,1, Wan-Long Chuang2, Chuan-Mo Lee3,
Ming-Lung Yu2, Sheng-Nan Lu3, Shun-Sheng Wu4, Li-Ying Liao5,
Hsing-Tao Kuo6, You-Chen Chao7, Shui-Yi Tung8, Sien-Sing Yang9,
Jia-Horng Kao1, Chen-Hua Liu1, Pei-Jer Chen1,
Ding-Shinn Chen1. 1National Taiwan University College of
Medicine and National Taiwan University Hospital; 2Kaohsiung
Medical University Hospital; 3Chang Gung Memorial
Hospital-Kaohsiung; 4Changhua Christian Hospital; 5Taipei City
Hospital; 6Chi Mei Medical Center; 7Tri-Service General
Hospital; 8Chia-Yi Chang Gung Memorial Hospital; 9Cathay
General Hospital
Objectives: Our recent study showed the potential for peginter-
feron alfa-2a and ribavirin combination therapy in these patients
– a high rate of HBsAg clearance was observed (11%) 24 weeks
post treatment in patients with HBeAg-negative disease. We
assessed HBsAg levels at baseline, during and after the end of
treatment.
Methods: HBsAg-positive patients coinfected with HCV received
peginterferon alfa-2a (180μg/week) for 48 weeks (in HCV geno-
type 1 in combination with ribavirin 1000/1200 mg/day) or for
24 weeks (for HCV genotype 2/3 in combination with ribavirin
800 mg/day). HBsAg was quantiﬁed at baseline, weeks 4, 12, end
of treatment (24 or 48 weeks) and 24 weeks post treatment (48
or 72 weeks) using the Abbott Architect assay. HBsAg data were
available for 120 of the 161 dual-infected patients.
Results: Of 120 patients, 74 received treatment for 48 weeks
and 46 received treatment for 24 weeks. Pretreatment median
serum HBsAg was 156 IU/mL. At the end of follow up, 14 patients
(11.7%) had cleared HBsAg. Baseline HBsAg levels in approxi-
mately 80% of patients clearing HBsAg at end of therapy or follow
up were low (<1 IU/mL). 21 (46%) patients who had received
therapy for 24 weeks achieved HBsAg levels <10 IU/mL at the
end of follow-up; 37 (50%) patients who had received therapy
for 48 weeks achieved HBsAg levels <10 IU/mL at the end of
follow-up.
Conclusions: HBV/HCV coinfected patients treated for 24 or 48
weeks with low baseline levels of HBsAg could potentially clear
HBsAg.
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PL-006 Study on detection of resistant genes in common
clinical bacteria used a multiplex real-time PCR
and melt temperature curve assay
Xuedong Lu*, Chengjing Xia, Lie Huang, Qiong Wang, Jian Liu,
Guangcheng Lin, Jiehong Wei. Shenzhen Futian Hospital
Objective To construct a multiple detection platform for
macrolides and beta-lactamases resistant genes of clinical bac-
teria.
Methods To detected ermA, ermB, ermC, msrA genes for
macrolides and tem, shv, ctx-m-1 team, ctx-m-9 team genes
for beta-lactamases resistant genes screening by using multi-
plex real-time SYBR Green I PCR combining melt temperature
curve assay. Resistant genes were detected and the results were
compared with phenotype results and sequencing results.
Results All the resistance genes of positive bacteria were demon-
strated by the optimize multiplex detection platform. The sen-
sibility was 104 CFU for multiple resistant gene bateria and 103
CFU for single resistant gene bateria. The detection results of
Plenary Presentations S29
136 staphylococci was 94.8% (129/136) accordance with the phe-
notype results and 100% accordance with the sequencing results.
Staphylococci were identiﬁed to common macrolides resistance
genes and the positive probability was 75.7% (103/136). The
results of 110 Escherichia coli and 94 Klebsiella pneumoniae was
97.1% (198/204) accordance with the phenotype results and 100%
accordance with sequencing results. Common beta-lactamases
resistance genes positive probability were 42.7% (47/110) in
Escherichia coli and 36.2% (34/94) in Klebsiella pneumoniae.
Conclusion Multiplex real-time SYBR Green I PCR combining
melt temperature assay can screen rapidly and identify accu-
rately common macrolides resistance genes in staphylococci and
beta-lactamases resistance genes in Escherichia coli or Klebsiella
pneumoniae. The multiple detection platform can be applied to
detect common resistance genes in clinical specimen and the
method has important value in instructing clinician to prescribe
accurate antibiotics and monitoring for resistance epidemiology.
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PL-007 CD14highCD16+, rather than CD14lowCD16+
monocytes, correlate with disease progression in
chronic HIV-infected patients
Beibei Wang*,1,2, Junyan Han1,2, Ning Han2, Yan Zhao3,
Chuan Song1, Xin Feng1, Yu Mao1, Fujie Zhang2,3,
Hongxin Zhao2, Hui Zeng1,2. 1Institute of Infectious Diseases,
Capital Medical University, Beijing, China; 2Division of
Infectious Diseases, Beijing Ditan Hospital, Beijing, China;
3Chinese Center for Disease Control and Prevention, National
Center for AIDS, Division of Treatment and Care, Beijing, China
Objectives: CD14+CD16+ monocytes are an important cellular
target for HIV-1 entry and expand in the peripheral blood
of HIV-infected individuals. Since CD14+CD16+ monocytes are
a heterogeneous population and consist of CD14highCD16+ and
CD14lowCD16+ subsets, we evaluated the effects of HIV infection
on distinct subsets of CD16+ monocytes.
Methods: Untreated HIV-infected patients were recruited to in-
vestigate the relationship between the proportions of monocyte
subsets with plasma viral loads and CD4+ T cell counts. Pa-
tients receiving HAART were followed in a cross-sectional and
longitudinal study, respectively.
Results: Compared with CD14lowCD16+, CD14highCD16+ monocytes
showed higher levels of CD64 and HLA-DR antigens, which implies
that these two distinct subsets have different immunoregula-
tory phenotypes. In HAART-naïve patients, elevated proportions
of CD14highCD16+ monocytes were correlated with increased vi-
ral loads, as well as decreased CD4+ T-cell counts, whereas
CD14lowCD16+ monocytes did not show such correlation with dis-
ease progression. Of importance, HAART recovered the propor-
tion of CD14highCD16+ monocytes, whereas CD14lowCD16+ mono-
cytes did not decrease during 1 year of antiviral therapy.
Conclusions: Taken together, our observations elucidate distinct
immune responses of monocyte subsets during HIV infection and
antiviral therapy, and provide new insight into the roles of innate
immunity in HIV-related pathogenesis.
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PL-008 Receptor binding proﬁle of H5N1 inﬂuenza virus
correlates with glycosylation of HA and length of
NA stalk
Chao-Tan Guo*, En-Kang Wo, Hai-Bo Wu. Zhejiang Academy of
Medical Sciences
Background: Transmission of H5N1 inﬂuenza viruses from poultry
to humans and from humans to humans is currently inefﬁcient.
However, when such transmission occurs, the case-fatality ratio
is high.
Methods: 55 H5N1 isolates in recent years could be divided into
three groups based on receptor binding speciﬁcity for the avian-
type, the human-type and both types of receptors. Analyses of
HA and NA sequences of these viruses revealed motifs associated
with the receptor binding proﬁle. We determined that glycosyla-
tion of HA and length of NA stalk inﬂuenced the receptor binding
speciﬁcities of viruses using a reverse genetic system. The viruses
having two glycosylation at positions 158 and 169 in HA lacked
the binding activities to human-type receptor.
Results: Data of their binding speciﬁcity and their replication
in different type cells indicates the length of NA stalk was as-
sociated with the receptor binding proﬁle, further act on the
replication of viruses. Viruses which match with HA having two
glycosylation sites and short-stalked NA bound preferentially to
avian-type receptor and adapted to poultry. Viruses which match
with HA lacking glycosylation and short-stalked NA bound both
avian- and human-type receptors.
Conclusion: We found two critical factors favoring H5N1 infec-
tion from humans to humans: no glycosylation site at 158 of
HA, and NA with a full-length stalk. Such viruses might be more
likely to be transmitted from humans to humans. These features
are important molecular markers of H5N1 viruses with increased
pandemic potential.
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PL-009 Interferon and nucleoside/tide analog reduce risk
of hepato-cellular carcinoma among hepatitis B
patients: a meta-analysis
Kelvin K.F. Tsoi *, Vincent W.S. Wong, Henry L.Y. Chan, Joseph
J.Y. Sung. Institute of Digestive Disease, Chinese University of
Hong Kong
Objectives: The effects of treatment in preventing hepatocellu-
lar carcinoma (HCC) is not clear. We studied effects of interferon
(IFN) or nucleoside/tide analog (NA) on the risk of developing
HCC in Chronic hepatitis B infection (CHB) patients.
Methods: Full publications and abstracts from MEDLINE, EMBASE,
the Cochrane Central Register of Controlled Trials, the Database
of Abstracts of Reviews of Effects, and the International Pharma-
ceutical Abstracts were retrieved. Abstracts published in DDW,
UEGW and APDW over the past 10 years were also manually
searched. Both randomized controlled trials and case-control
studies were included. The relative risks (RR) of HCC with or
without CHB treatment were studied.
Results: Twelve studies compared IFN (n=1,292) versus control
(n=1,450) and showed that the overall risk of HCC after treat-
ment was reduced by 34% (RR 0.66, 95%CI 0.48-0.89). Beneﬁt is
more signiﬁcant among patients with early cirrhosis than those
without. Four studies compared the risk of HCC development af-
ter using NA (n=1,267) versus control (n=1,022). The overall risk
of HCC after treatment was reduced by 78% (RR 0.22, 95%CI 0.10-
0.50). HBeAg positive patients showed more signiﬁcant reduced
HCC risk with treatment. Patients with cirrhosis beneﬁted more
from the treatment than those without cirrhosis. Resistance to
NA has obviated the beneﬁt of the treatment.
Conclusions: Both IFN and NA showed signiﬁcant reduction in
risk of developing HCC. While IFN treatment beneﬁted patients
with early cirrhosis, NA treatment beneﬁted patients with HBeAg
positive CHB infection, with or without drug resistance or early
cirrhosis.
